Yayın:
The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey

Sadeleştirilmiş öğe sayfası
dc.contributor.authorTurhal, Serdar
dc.contributor.authorDeniz Can Güven
dc.contributor.authorAhmet Anıl Özlük
dc.contributor.authorRashad İsmayılov
dc.contributor.authorEmel Mutlu
dc.contributor.authorOlçun Ümit Ünal
dc.contributor.authorİbrahim Yıldız
dc.contributor.authorYakup İriağaç
dc.contributor.authorSerdar Turhal
dc.contributor.authorSinem Akbaş
dc.contributor.authorErtuğrul Bayram
dc.contributor.authorTuğba Akın Telli
dc.contributor.authorFatma Paksoy Türköz
dc.contributor.authorMelike Özçelik
dc.contributor.authorMert Erciyestepe
dc.contributor.authorOğuzhan Selvi
dc.contributor.authorBurcu Gülbağcı
dc.contributor.authorİsmail Ertürk
dc.contributor.authorZehra Sucuoğlu İşleyen
dc.contributor.authorSeda Kahraman
dc.contributor.authorMutianur Özkorkmaz Akdağ
dc.contributor.authorBuket Hamitoğlu
dc.contributor.authorİlkay Tuğba Ünek
dc.contributor.authorÇağlar Ünal
dc.contributor.authorİlhan Hacıbekiroğlu
dc.contributor.authorÇağatay Arslan
dc.contributor.authorAbdulmunir Azizy
dc.contributor.authorKaan Helvacı
dc.contributor.authorUmut Demırcı
dc.contributor.authorÖmer Dızdar
dc.contributor.authorMert Başaran
dc.contributor.authorErdem Göker
dc.contributor.authorMehmet Alı Nahıt Şendur
dc.contributor.authorŞuayib Yalçın
dc.contributor.orcid0000-0002-4452-2076
dc.contributor.orcid0000-0002-6924-9467
dc.contributor.orcid0000-0002-7093-2722
dc.contributor.orcid0000-0002-1008-2527
dc.contributor.orcid0000-0001-7698-3574
dc.contributor.orcid0000-0002-2884-7970
dc.contributor.orcid0000-0001-7411-1705
dc.contributor.orcid0000-0002-7197-211X
dc.contributor.orcid0000-0001-8713-7613
dc.contributor.orcid0000-0001-6535-6030
dc.contributor.orcid0000-0003-0406-715X
dc.contributor.orcid0000-0002-7590-6101
dc.contributor.orcid0000-0002-5720-8254
dc.contributor.orcid0000-0001-6835-0988
dc.contributor.orcid0000-0002-0045-8009
dc.contributor.orcid0000-0002-5328-6554
dc.contributor.orcid0000-0003-2002-3931
dc.contributor.orcid0000-0002-9124-6123
dc.contributor.orcid0000-0003-3245-1570
dc.contributor.orcid0000-0002-0333-7405
dc.contributor.orcid0000-0002-3783-7432
dc.contributor.orcid0000-0002-5068-6472
dc.contributor.orcid0000-0002-8394-8168
dc.contributor.orcid0000-0002-4833-6721
dc.contributor.orcid0000-0003-0911-9078
dc.contributor.orcid0000-0001-5437-134X
dc.contributor.orcid0000-0001-6180-713X
dc.contributor.orcid0000-0001-7021-6139
dc.contributor.orcid0000-0001-7850-6798
dc.date.accessioned2025-11-13T10:27:29Z
dc.date.issued2023-11-10
dc.identifier.doihttps://doi.org/10.1097/md.0000000000035950
dc.identifier.endpagee35950
dc.identifier.issn0025-7974
dc.identifier.issue45
dc.identifier.openalexW4388562853
dc.identifier.startpagee35950
dc.identifier.urihttps://hdl.handle.net/11421/4210
dc.identifier.urihttps://doi.org/10.1097/md.0000000000035950
dc.identifier.volume102
dc.language.isoen
dc.relation.ispartofMedicine
dc.rightsopenAccess
dc.subjectMedicine
dc.subjectInternal medicine
dc.subjectBevacizumab
dc.subjectHepatocellular carcinoma
dc.subjectConcomitant
dc.subjectGastroenterology
dc.subjectAtezolizumab
dc.subjectProportional hazards model
dc.subjectAdverse effect
dc.subjectSurgery
dc.subjectCancer
dc.subjectChemotherapy
dc.subjectNivolumab
dc.subject.sdg3
dc.titleThe safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5108484042

Dosyalar

Koleksiyonlar

Publications